![]() |
市场调查报告书
商品编码
1657987
手术中放射线治疗市场评估,各类产品·服务,各技术,各用途,各最终用途,各地区,机会及预测,2018-2032年Intraoperative Radiation Therapy Market Assessment, By Products and Services, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
全球术中放射治疗市场预计将从 2024 年的 601.5 亿美元增长到 2032 年的 966 亿美元,在 2025-2032 年预测期内的复合年增长率为 6.10%。市场的成长得益于开发新技术解决方案的投资增加、癌症患者数量的增加、政府支持性政策和举措的出台、人口老龄化的增长以及术中放射治疗的接受度不断提高。
世界各国政府都在加强对加强本国医疗保健基础设施的投资,从而对术中放射治疗市场的扩张产生正面影响。例如,沙乌地阿拉伯政府在 "2030愿景" 计画下,致力于实现医疗设备和服务的现代化、改善医疗设施的可及性以及扩大私营部门投资的作用。这些措施预计将增加对先进治疗解决方案和服务的需求,包括术中放射治疗,为市场提供有利可图的成长机会。
此外,对术中放射治疗临床试验的日益重视也推动了市场扩张。临床试验已经建立了治疗方案并增加了对术中放射治疗的信心。此外,临床试验已证明术中放射治疗具有多种益处,包括改善患者预后、最大限度地减少正常组织的放射暴露以及缩短治疗间隔。
对技术先进的成像过程的投入不断增加,促进了成像解决方案的开发,这些解决方案可在手术过程中精确瞄准和可视化肿瘤,从而提高术中放射治疗的功效和精确度。这些措施进一步推动了术中放射治疗的采用,对市场扩张产生了正面影响。
此外,最近的研究和发现表明,将术中放射治疗与手术和化疗相结合可以改善治疗效果,从而对医护人员和患者更具吸引力。术中放射治疗正迅速变得越来越流行,因为它最大限度地减少了对周围组织健康的损害。
所有市场区隔均提供所有对象地区和国家/地区。
上述公司不依市场占有率排序,并且可能会根据研究工作期间获得的资讯进行更改。
Global intraoperative radiation therapy market is projected to witness a CAGR of 6.10% during the forecast period 2025-2032, growing from USD 60.15 billion in 2024 to USD 96.60 billion in 2032. The market's growth is augmented by the increasing investments towards developing novel technological solutions, rising cancer cases, the introduction of supportive government policies and initiatives, expansion of the ageing population, and increasing acceptance of intraoperative radiation therapy.
Various governments across the globe are increasingly investing in enhancing their country's healthcare infrastructure, positively influencing the expansion of the intraoperative radiation therapy market. For instance, under the Vision 2030 program, the government of Saudi Arabia is focusing on the modernization of healthcare equipment and services, improving access to healthcare facilities, and increasing the role of investments from the private sector. Such efforts are expected to bolster the requirement for advanced therapeutic solutions and services including intraoperative radiation therapy and provide lucrative growth opportunities for the market.
Growing emphasis on clinical trials for intraoperative radiation therapy is also supporting the market's expansion as clinical trials are allowing the establishment of treatment protocols and increasing confidence in the procedure. Clinical trials have also demonstrated the various benefits of intraoperative radiation therapy including improved patient outcomes, minimal exposure to normal tissues, and limited treatment intervals.
Rising investments towards technologically advanced imaging processes are allowing the development of imaging solutions that aid in the precise targeting and visualization of tumors during surgical procedures, enhancing the efficacy and precision of intraoperative radiation therapy. Such efforts are further augmenting the adoption of the procedure and positively influencing the expansion of the market.
Moreover, recent studies and findings have also shown that combining intraoperative radiation therapy with surgery and chemotherapy improves treatment outcomes, increasing its appeal to medical professionals and patients. The deployment of intraoperative radiation therapy is rapidly soaring as the procedure minimizes the damage caused to the health of surrounding tissues.
Surging Investments in Healthcare Infrastructure and Oncology Research
The growing emphasis on enhancing healthcare infrastructure and cancer research activities is another major factor supporting the growth of the global intraoperative radiation therapy market. Various public and private healthcare institutions and governments are significantly investing towards expanding oncology treatment centers and integrating advanced treatment options including novel radiation therapy technologies. As the healthcare sector witnesses the upgradation of technology and expansion of capabilities, the acceptance and adoption of intraoperative radiation therapy are expected to increase significantly.
Additionally, various researchers are being rewarded with grants to improve cancer treatments, further providing lucrative growth opportunities for the market by fostering innovation and augmenting the availability of advanced treatment options. For instance, in January 2025, two projects led by the University of Wollongong's (UOW) Centre for Medical Radiation Physics (CMRP), were awarded over USD 2 million in funding from the National Health Medical Research Centre (NHMRC). Such efforts improve patient outcomes while supporting the rising adoption of innovative radiation therapies in different clinical settings.
Robust Product Pipeline and Promising Clinical Trials Support Market Expansion
The rising number of clinical trials for intraoperative radiation therapy is bolstering the growth of the market as they aid in propelling the applications of intraoperative radiation therapy for various types of cancer such as colorectal, lung, breast, and brain, among others. Additionally, clinical trials also play a crucial role in showcasing the various benefits associated with intraoperative radiation therapy as opposed to conventional radiotherapy. Thus, various healthcare companies, cancer research institutes, and research organizations are significantly investing in clinical trials.
For instance, the University of California is conducting an interventional study to evaluate the side effects of intraoperative radiation therapy and its effectiveness in patients suffering from breast cancer who are undergoing breast-conserving surgery. The study is expected to conclude in December 2028 with a primary objective of systemically assessing long-term and acute toxicity, and outcomes of intraoperative radiation therapy in a broader cohort of patients.
Breast Cancer Accounts for Significant Share of the Market
Breast cancer treatment is expected to account for a significant share of the market over the forecast period owing to the increasing acceptance of intraoperative radiation therapy in comparison to conventional radiation therapy for treating early-stage breast cancer. After the removal of the cancer cells from the breast, the intraoperative radiation therapy machine is placed at an appropriate location for determining the required dosage for radiation based on evidence-based guidelines. The radiation is aimed at where the risk of cancer recurrence is the highest.
Due to the rising prevalence of the condition, the demand for effective treatment options that eliminate or reduce the chances of cancer recurrence is significantly increasing. As per the estimates of the National Breast Cancer Foundation, in 2024, 2,800 men and 310,720 women were diagnosed with invasive breast cancer in the United States. The foundation also estimates that approximately 1 in 8 women in the country will be diagnosed with breast cancer during their lifetime. Thus, various medical device and pharmaceutical companies are focusing on collaborating with oncology centers to commercialize and develop intraoperative radiation therapy solutions for breast cancer, further providing lucrative growth opportunities for the market.
North America Region Holds Major Market Share
The expansion of the North America intraoperative radiation therapy market can be attributed to the increasing incidences of cancer, the rising availability of advanced therapeutic solutions, and growing investments in the healthcare sector. According to the statistics released by the National Cancer Institute in May 2024, approximately 2,001,140 new cancer cases were expected to be diagnosed in the United States in 2024. Additionally, the growing preference for minimally invasive procedures in the region is also bolstering the demand for intraoperative radiation therapy. The therapeutic procedure allows the delivery of a high dose of radiation at the tumor bed during the surgical procedure, reducing the duration of the treatment and improving patient outcomes.
Additionally, the strong presence of leading research institutions and market players supports the market's expansion in North America as they significantly invest in research and development activities, ensuring the availability of advanced treatment options in countries such as the United States and Canada. Furthermore, the increasing awareness among the patient population and healthcare professionals about the various advantages of intraoperative radiation therapies is also augmenting their adoption in North America. Healthcare institutions across the region are actively investing in training medical professionals on using intraoperative radiation therapy.
Future Market Scenario (2025 - 2032F)
As per the global intraoperative radiation therapy market analysis, the market is expected to witness significant growth over the forecast period due to the rapid expansion of the healthcare industry, increasing preference for minimally invasive technologies, rising cases of cancer, and growing focus on the development of advanced therapeutic solutions.
According to the estimates of the American Cancer Society, the number of cases of cancer is expected to reach 35 million, by 2050. This increase is expected to bolster the utilization of intraoperative radiation therapy as the procedure uses innovative equipment for delivering intraoperative radiation therapy, electron beams, or x-rays directly, immediately eliminating cancer cells after the surgery.
Technological innovations including electronic brachytherapy devices and mobile line accelerators are enhancing the accessibility and efficacy of intraoperative radiation therapy systems. Such advancements are expected to aid in precisely targeting tumor cells during surgical procedures, ensuring improved patient outcomes due to minimization of damage caused to healthy tissues.
The increasing efforts of governments of various countries to enhance their healthcare sector and boost the availability of advanced medical technologies are also expected to provide lucrative growth opportunities for the market.
Key Players Landscape and Outlook
The market's key players are actively engaging in mergers and acquisitions to strengthen their position and ensure the availability of advanced technologies in various regions across the globe. In February 2023, Viewpoint Molecular Targeting, Inc. and Isoray, Inc. announced the successful completion of their merger. The companies adopted a new name Perspective Therapeutics Inc. and are focusing on the advancing of cancer treatments with the help of imaging technologies, radiopharmaceuticals, and radiation therapies. Perspective Therapeutics is also developing a novel pipeline of proprietary targeting peptides for diagnosing tumors and delivering Targeted Alpha Therapies (TATs).
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.